Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving ...

Several headwinds have pushed Regeneron 's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is ...

EYLEA and Dupixent sales drive company revenue to new records. R&D expenses are projected to reach $5 billion, but the business remains highly profitable. Regeneron is liquid and solvent, but growth ...

Regeneron's share price has climbed by more than 100% over five years and is trading near its record high. The company sells a variety of products across indications and has a solid pipeline that ...

Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control thrombosis ...

Regeneron Pharmaceuticals announced initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab, used in combination with carfilzomib or bortezomib, for patients with ...

CompanyOverview|NASDAQ:REGN] Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major ...

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long-term ...

Regeneron announced that patients taking an 8 mg high-dose version of its ophthalmology drug Eylea (already approved at a 2 mg dose) were largely able to maintain longer dosing intervals than the ...

The Food and Drug Administration didn't approve Regeneron's higher-dose version of Eylea. Regeneron isn't concerned, as the decision wasn't a result of any issues relating to the drug's safety or ...